Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hansa Biopharma AB's Revenue for the
three
months ended in Mar. 2026 was kr34.6 Mil. Hansa Biopharma AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr62.0 Mil.
Hence, Hansa Biopharma AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.56.
Hansa Biopharma AB (CHIX:HNSAs) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Hansa Biopharma AB Receivables Turnover Related Terms
Hansa Biopharma AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:HNSAS vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB (CHIX:HNSAS) has a Receivables Turnover of 0.56 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hansa Biopharma AB and its competitors. According to the industry distribution chart, Hansa Biopharma AB ranks #743 out of 841 companies in the Biotechnology industry, placing it in the top 88.3%.
Is Hansa Biopharma AB's Receivables Turnover too high?
Hansa Biopharma AB's current Receivables Turnover is 0.56. The Biotechnology industry median Receivables Turnover is 5.29. Hansa Biopharma AB's value of 0.56 is 89.4% below this industry median. Based on the distribution chart, Hansa Biopharma AB ranks #743 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hansa Biopharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hansa Biopharma AB ranks #743 out of 841 companies for Receivables Turnover. This places Hansa Biopharma AB in the lower half of its industry. The industry median Receivables Turnover is 5.29. Hansa Biopharma AB's value of 0.56 is 89.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansa Biopharma AB's current Receivables Turnover of 0.56 is 89.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hansa Biopharma AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansa Biopharma AB's current Receivables Turnover is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Receivables Turnover of 0.56. The stock's GF Value™ is kr19.38, compared to a current price of kr25.64 — trading 32.3% above its estimated fair value. The current Receivables Turnover is 0.56 and 89.4% below the Biotechnology industry median of 5.29. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Receivables Turnover is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr25.64 is trading 32.3% above its estimated GF Value™ of kr19.38.
Key valuation signals for CHIX:HNSAS:
Receivables Turnover: 0.56
GF Value™: kr19.38 vs. price of kr25.64 (32.3% above fair value)
Industry Position: 89.4% below the Biotechnology median (#743 of 841)
No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for CHIX:HNSAS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HNSAS has been successfully added to your 
